ReviewCurrent rheumatology reports2021
Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist.
Review in Current rheumatology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Neuromyelitis optica spectrum disorder associated with cutaneous lupus and multidrug immunosuppressant hypersensitivity.BMJ case reports · 2026Article
- Microglial PD-1/PD-L1 axis in CNS demyelinating diseases: a dual immunoregulatory perspective.Frontiers in cellular neuroscience · 2026Review
- AQP4+ NMOSD, MDA5+ Clinically Amyopathic Dermatomyositis and sHLH in a Pediatric Patient: A Case Report and Literature Review.Journal of inflammation research · 2026Article
- Drug-Induced Lupus Erythematosus After 14 Years of Carbamazepine Use in a Patient With Neuromyelitis Optica Spectrum Disorder: A Case Report.The American journal of case reports · 2025Article
- Mimickers of Systemic Lupus Erythematosus: Case Series and Literature Overview.Journal of clinical medicine · 2025Article
- Evaluation of CD3+CD56+ NKT and CD19+ B Cells in Assessing the Relapse of Neuromyelitis Optica Spectrum Disorder Patients Treated With Rituximab.Brain and behavior · 2025Article
- Review
- Concomitant Sjögren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence.Arthritis research & therapy · 2025Article
- AQP4 antibody-seropositive neuromyelitis optica spectrum disorder in a patient with mixed connective tissue disease: a case report.AME case reports · 2025Article
- Article
- A Chinese girl with neuromyelitis optica spectrum disorder coexisting with primary Sjogren's syndrome: a case report and literature review.Frontiers in immunology · 2025Review
- Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies.Frontiers in neurology · 2025Article
- Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and mixed connective tissue disease: a case report.Frontiers in immunology · 2025Article
- Case Report: Contiguous presentation of anti-MDA5 juvenile dermatomyositis and anti-AQP4 neuromyelitis optica spectrum disorder in an adolescent patient.Frontiers in pediatrics · 2024Article
- Area postrema syndrome secondary to primary Sjogren's syndrome.Rheumatology advances in practice · 2024Article
- Assessment of central nervous system vasculitis in children based on high-resolution vascular wall imaging.Rheumatology advances in practice · 2024Article
- Case report: Overlap syndrome of neuromyelitis optica spectrum disorder with anti-Argonaute antibodies.Frontiers in immunology · 2024Article
- Neuromyelitis Optica: Pathogenesis Overlap with Other Autoimmune Diseases.Current allergy and asthma reports · 2023Review
- Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- A Race to the Finish.The New England journal of medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review the pathophysiology, presentation, and treatment of neuromyelitis optica spectrum disorder (NMOSD) and its association with systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). RECENT
findingsNMOSD is an autoimmune disorder of the central nervous system that primarily targets astrocytes. Although the prevalence is unknown, the coexistence of NMOSD and SLE/SS is well-recognized. Patients with both NMOSD and SLE or SS require may require unique approaches to diagnosis and management. Coexistence of NMOSD and SLE/SS is important for the rheumatologist and neurologist to be able to recognize. For the rheumatologist, NMOSD and its neurologic symptoms represent a distinct disease process from neurologic complications of the patient's underlying connective tissue disease, and it requires distinct acute and chronic management. For the neurologist, the coexistence of SLE and SS can help to establish a diagnosis of NMOSD, or in some situations, the development of neurologic symptoms secondary to NMOSD can lead to the diagnosis of connective tissue disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.